| 2026-08-07 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-08-06 | Press release | Ligand Reports Second Quarter 2026 Financial Results |
| 2026-08-06 | Deck | Ligand Second Quarter 2026 Earnings Call |
| 2026-08-06 | Press release | Press release · Q2 2026 · Aug 2026 |
| 2026-08-06 | 8-K | Form 8-K, Item 2.02 results |
| 2026-07-23 | Press release | Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026 |
| 2026-07-14 | Press release | Download , Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty |
| 2026-07-14 | Press release | Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets |
| 2026-07-14 | 8-K | Form 8-K, Item 1.01 |
| 2026-06-25 | 8-K | Form 8-K, Item 1.01 |
| 2026-06-23 | Press release | Download , Ligand Announces Pricing of Upsized $625 Million Convertible Senior Notes Offering, (opens in |
| 2026-06-22 | Press release | Download , Ligand Announces Proposed Offering of $550 Million of Convertible Senior Notes Due 2031, (open |
| 2026-06-22 | 8-K | Form 8-K, Item 1.01 |
| 2026-06-10 | Press release | Ligand Announces 2026 Investor Day in New York City |
| 2026-06-09 | 8-K | Form 8-K, Item 5.02 |
| 2026-05-27 | Press release | Download , Ligand to Participate in June Investor Conferences |
| 2026-05-27 | Press release | Ligand to Participate in June Investor Conferences |
| 2026-05-18 | 8-K | Form 8-K, Item 1.01 |
| 2026-05-08 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-05-07 | Press release | Ligand Reports First Quarter 2026 Financial Results |
| 2026-05-07 | Press release | Press release · Q1 2026 · May 2026 |
| 2026-05-07 | Deck | Presentation of Q1 2026 |
| 2026-05-07 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-05 | Press release | Download , Ligand to Participate in May Investor Conferences |
| 2026-05-05 | Press release | Ligand to Participate in May Investor Conferences |
| 2026-04-30 | 8-K | Form 8-K, Item 1.02 |
| 2026-04-27 | Press release | Download , Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a L |
| 2026-04-27 | Deck | Investor presentation · Apr 2026 |
| 2026-04-27 | Press release | Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biop |
| 2026-04-27 | 8-K | Form 8-K, Item 1.01 |
| 2026-04-22 | Press release | Ligand to Report First Quarter 2026 Financial Results on May 7, 2026 |
| 2026-04-22 | Press release | Ligand to Report First Quarter 2026 Financial Results on May 7, 2026 |
| 2026-04-21 | Proxy | Definitive proxy statement |
| 2026-04-14 | Press release | Download , Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS, April 14 |
| 2026-04-14 | Press release | Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS |
| 2026-03-26 | Press release | Download , Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team, (o |
| 2026-03-04 | Press release | Download , Ligand to Participate in March Investor Conferences |
| 2026-02-28 | Transcript | Q4 FY25 earnings call transcript |
| 2026-02-27 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-02-26 | Press release | Download , Ligand Reports Fourth Quarter and Full Year 2025 Financial Results |